IQUO-Ledger- Prospective non-interventional study for the characterisation of routine practice of Cabazitaxel and other therapyoptions for treatment of patients with metastasizing castration resistent prostate cancer (mCRPC) in established doctors´practice with emphasis on oncological urology

IQUO-Ledger- Prospective non-interventional study for the characterisation of routine practice of Cabazitaxel and other therapyoptions for treatment of patients with metastasizing castration resistent prostate cancer (mCRPC) in established doctors´practice with emphasis on oncological urology - HOPE (NIS Jevtana)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004355

Enrollment

500

Registered

2012-09-05

Start date

2012-09-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Application of Cabazitaxel as single treatment regimen Group 2: Application of Cabazitaxel as adjunction

Eligibility

Sex/Gender

Male

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients with prostate cancer (mestatsizing, castration resistent), who start a treatment with Cabazitaxel, Age over 18 years, patient informed consent

Exclusion criteria

Exclusion criteria: patient who participate in another study, earlier treatment with Cabazitaxel

Design outcomes

Primary

Measure	Time frame
The primary aim is the description of routine application of Cabazitaxel and foregoing/subsequent therapy options for treatment of patients with mCRPC in established doctor´s practices with emphasis on oncological urology.	—

Secondary

Measure	Time frame
The secondary aim is the description of through the medical evalued effectiveness including response, control of desease, progressionfree survival, time to therapy failure and overall survival.	—

Countries

Germany

Contacts

Public ContactHeribert Stiegler

OnkoDataMed GmbH

heribert.stiegler@onkodatamed.de030/64387560

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026